We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
3,739.25-26.25(-0.70%)Dow Futures
30,705.00-173.00(-0.56%)Nasdaq Futures
12,332.00-123.00(-0.99%)
Geron Corporation (GERN)
1.7200 -0.05 (-2.82%)
After hours: 7:58PM EST
Chart Events
Performance Outlook
| Previous Close | 1.7000 |
| Open | 1.6800 |
| Bid | 1.7600 x 34100 |
| Ask | 1.7700 x 21500 |
| Day's Range | 1.6300 - 1.8000 |
| 52 Week Range | 0.7500 - 2.4000 |
| Volume | 6,211,284 |
| Avg. Volume | 3,654,735 |
| Market Cap | 549.535M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3350 |
| Earnings Date | Mar 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Fair Value
Related Research
- Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
- Analyst Report: Gilead Sciences, Inc.
- Zacks
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.
- Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 431,600 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
- Simply Wall St.
Is Geron (NASDAQ:GERN) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Business Wire
Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.
- Insider Monkey
Is GERN A Good Stock To Buy Now?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- Business Wire
Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
- Business Wire
Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS). Data from the IMerge Phase 2 were recently presented at the American Society of Hematology Annual Meeting and support the ongoing Phase 3.
- Business Wire
Geron Reports Ten Imetelstat Presentations at American Society of Hematology Annual Meeting
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentations containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting. The presentations are available at www.geron.com/r-d/publications.
- Business Wire
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common stock as an inducement to a newly-hired employee in connection with commencement of employment with the Company.
Analyst Price Targets (6)
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: to Buy | 8/26/2020 | |
| Initiated | Stifel: to Buy | 8/3/2020 | |
| Maintains | Cantor Fitzgerald: to Overweight | 6/1/2020 | |
| Maintains | B. Riley FBR: to Buy | 5/29/2020 | |
| Maintains | BTIG: to Buy | 4/3/2020 | |
| Maintains | B. Riley FBR: to Buy | 3/17/2020 |
Company Profile
149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
United States
650 473 7700
http://www.geron.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 45
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
